# crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/crvdac3-alleviates-ferroptosis-by-impeding-hspb1-ubiquitination-and-confers/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yutian Zou,Anli Yang,Bo Chen,Xinpei Deng,Jindong Xie,Jindong Xie,Danian Dai,Jinhui Zhang,Hailin Tang,Tao Wu,Zhigang Zhou,Xiaoming Xie,Jin Wang |
| Citations | 95 |
| DOI | 10.1016/j.drup.2024.101126 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4401360741 |
| PMID | 39243601 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Xiaoming Xie](https://scholariq.org/researchers/xiaoming-xie/)

## Paper primary topic

- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)

## Paper topics

- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)
- [Clusterin in disease pathology](https://scholariq.org/topics/clusterin-in-disease-pathology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.